BioPontis Chair, Erik Tambuyzer, co-authors article for December issue of Nature research journal

BioPontis Chair, Erik Tambuyzer, co-authors article for December issue of Nature research journal

December 18, 2019

The gap between rare disease identification and effective rare disease therapies is still vast. The December issue of Nature’s research journal Nature Reviews Drug Discovery, takes a closer look at available therapies and their application to rare disease as well as challenges and progress in making advances toward available treatments. Please read the published article Therapies for rare diseases: therapeutic modalities, progress and challenges ahead from lead author and BioPontis Alliance chairperson, Erik Tambuyzer among others from distinguished universities and research institutes discussing the current and future states of rare disease innovation.

PDF for download available in link above or on article site:
https://www.nature.com/articles/s41573-019-0049-9



About BioPontis Alliance for Rare Diseases

BioPontis Alliance for Rare Diseases is a 501c(3) public charity in the US (North Carolina) and a foundation of public utility (fup/son) in Belgium (Brussels). Managed by an international Board and executive team, BioPontis partners with patient organizations and clinical researchers to bridge the gap between promising science and new medicines. BioPontis Alliance for Rare Diseases is being established as a global non-profit, inviting corporate, private and foundation philanthropic support. More information, including how contributions to support our programs and mission can be made, at http://biopontisalliance.org.

Contacts:

David Spencer, PhD – CSO
BioPontis Alliance for Rare Diseases
+1.919.624.0841 (Raleigh, USA)
dspencer@biopontisalliance.org

Erik Tambuyzer, PhD – Chairperson
BioPontis Alliance for Rare Diseases
+32 475 61 57 11 (Brussels, Belgium)
Erik.Tambuyzer@biopontisalliance.org